Patents Examined by Stephen T Kapushoc
  • Patent number: 12252691
    Abstract: Oligonucleotides are provided herein that inhibit apolipoprotein(a) (LPA) expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with LPA expression.
    Type: Grant
    Filed: August 16, 2024
    Date of Patent: March 18, 2025
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek, Marc Abrams, Wen Han, Anton Turanov
  • Patent number: 12215389
    Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: February 4, 2025
    Assignee: Exact Sciences Corporation
    Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
  • Patent number: 12213464
    Abstract: Methods of identifying cattle having increased feed efficiency using a small panel of single nucleotide polymorphisms is provided. The method provides for using a thousand or less of such SNPs and includes using a panel of 250 or fewer SNPs. The method if useful with various cattle breeds including crossbred cattle. Provided are SNPs that are useful as markers with various traits associated with feed efficiency in cattle. Kits and methods of use are provided.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: February 4, 2025
    Assignee: The Governors of the University of Alberta
    Inventors: Graham Plastow, Mohammed Abo-Ismail
  • Patent number: 12209289
    Abstract: The compositions and methods are related to plant breeding and methods of identifying and selecting disease resistance genes. Provided are methods to identify novel genes that encode proteins providing plant resistance to various diseases and uses thereof. These disease resistant genes are useful in the production of resistant plants through breeding, transgenic modification, or genome editing.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: January 28, 2025
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Jennifer S Jaqueth, Bailin Li, Girma M Tabor, Shawn Thatcher
  • Patent number: 12209262
    Abstract: The present invention relates to polynucleotides comprising a Factor IX nucleotide sequence, wherein the Factor IX nucleotide sequence comprises a coding sequence that encodes a Factor IX protein or fragment thereof and wherein a portion of the coding sequence is not wild type. The present invention further relates to viral particles comprising a recombinant genome comprising the polynucleotide of the invention, compositions comprising the polynucleotides or viral particles, and methods and uses of the polynucleotides, viral particles or compositions.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: January 28, 2025
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Jenny Mcintosh
  • Patent number: 12203139
    Abstract: The present disclosure provides methods, systems, compositions, and kits for the high-throughput detection of multi-molecule biomarkers in a biological sample. The disclosed methods, systems, compositions, and kits utilize antibody-oligonucleotide tags to detect two or more molecules that are in close proximity.
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: January 21, 2025
    Assignee: TEMPUS AI, INC.
    Inventor: Timothy Rand
  • Patent number: 12194075
    Abstract: Described herein are polypeptides capable of self-assembling to form homo-oligomers, and methods for designing such polypeptides.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: January 14, 2025
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: David Baker, Jorge Fallas, George Ueda, William H. Sheffler, Vanessa Nguyen
  • Patent number: 12194055
    Abstract: SLC46A3 has been identified as a lipid-based nanoparticle-specific biomarker predictive of nanoparticle-cancer cell affinity. SLC46A3 has a strong inverse association with lipid-based nanoparticle uptake across multiple nanoparticle formulations. Tissues with decreased expression levels of SLC46A3 have a greater uptake of lipid-based nanoparticles. The inverse relationship of SLC46A3 expression in tumor tissue and affinity for lipid-based nanoparticles has therapeutic and diagnostic implications, including cancer therapy and diagnosis, and identification of patients most likely to benefit from a lipid-based nanotherapeutic for improved stratification in clinical trials.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: January 14, 2025
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Natalie Boehnke, Joelle Payne Straehla, Angela Koehler, Paula Hammond
  • Patent number: 12195805
    Abstract: Methods and compositions are provided for determining a subtype of Muscle Invasive Bladder Cancer (MIBC) in an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for MIBC. Also provided herein are methods and compositions for determining the response of an individual with a MIBC subtype to a therapy such as immunotherapy.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: January 14, 2025
    Assignees: GeneCentric Therapeutics, Inc., University of North Carolina at Chapel Hill
    Inventors: Hawazin Faruki, Greg Mayhew, Myla Lai-Goldman, Charles Perou
  • Patent number: 12180547
    Abstract: The present disclosure relates to methods of detecting gene expression in a biological sample from an animal. More specifically, this disclosure relates to methods of detecting risk for a catastrophic injury in an animal, such as a non-human athletic animal, based on the expression of select genes within a biological sample from the animal, which can be determined using mRNA expression analysis.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: December 31, 2024
    Assignee: University of Kentucky Research Foundation
    Inventors: Allen E. Page, David W. Horohov
  • Patent number: 12173372
    Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: December 24, 2024
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoshi Kondou, Hitoshi Nobumasa, Satoko Kozono, Hiroko Sudo, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
  • Patent number: 12157919
    Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: December 3, 2024
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Junpei Kawauchi, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Hiroko Sudo, Atsushi Ochiai, Motohiro Kojima
  • Patent number: 12139766
    Abstract: The present invention relates to refined prognostic clinical tools, methods, and kits for the evaluation of risk and treatment of distant recurrence in ER+/HER2? breast cancer patients.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: November 12, 2024
    Assignees: Istituto Europeo di Oncologia S.r.l., Fondazione Istituto Firc di Oncologia Molecolare (IFOM), Universita degli Studi di Milano (University of Milan)
    Inventors: Pier Paolo Di Fiore, Salvatore Pece, Manuela Vecchi, Stefano Confalonieri
  • Patent number: 12139762
    Abstract: Compositions and methods for the detection and treatment of ADHD are provided.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: November 12, 2024
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Hakon Hakonarson, Berta Almoguera, Lyam Vazquez, Patrick Sleiman
  • Patent number: 12129521
    Abstract: The present disclosure provides methods for detecting macro-heteroplasmy and/or micro-heteroplasmy in mitochondrial DNA. The methods can include detecting or monitoring the presence of heteroplasmy, and/or identifying a threshold level of heteroplasmy. In addition, the methods can be used for diagnosing a mitochondrial related disease or disorder, as well as for monitoring the efficacy of a therapy affecting mitochondrial DNA (mtDNA) in a subject having or suspected of having heteroplasmy.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: October 29, 2024
    Assignee: Imel Biotherapeutics, Inc.
    Inventors: Ryotaro Maeda, Daisuke Kami, Satoshi Gojo
  • Patent number: 12117462
    Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: October 15, 2024
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Hiroko Sudo, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
  • Patent number: 12104208
    Abstract: The invention relates to methods of predicting resistance to Piscirickettsia salmonis infection in a salmonid, the method comprising determining in the salmonid the alleles present at one or more DNA polymorphism within a QTL, and predicting the ability of the salmonid to be resistant to Piscirickettsia salmonis infection based on the determination of the alleles, wherein the QTL is: —(a) located in linkage group 21 (GenBank ID NC 034194.1) within the coho salmon genome, or in the chromosome of coho salmon that corresponds to that linkage group, when the salmonid is a coho salmon, or; (b) a QTL that is located in a linkage group that corresponds to linkage group 21 within the coho salmon genome, or in the chromosome of a salmonid that corresponds to that linkage group, when the salmonid is not a coho salmon. The invention further relates to probes and arrays useful in such method and related methods.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: October 1, 2024
    Assignee: BLUE GENOMICS CHILE SPA
    Inventors: Daniela Cichero Molina, Jorgen Odegard, Sven Korsvoll
  • Patent number: 12084720
    Abstract: This invention relates to methods and compositions for assessing the suitability of a graft for transplantation or implantation by measuring total and/or specific cell-free nucleic acids (such as cf-DNA) and/or cell lysis. Specifically, the method comprising obtaining an amount of total cf DNA and/or graft-specific cfDNA released from a potential graft (e.g., ex vivo), e.g., prior to contacting of the potential graft with blood cells of a potential recipient, and/or subsequent to contacting of the potential graft or cells thereof with blood cells from a potential recipient, assessing the amount(s) to determine the suitability of the potential graft for transplantation or implantation.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: September 10, 2024
    Assignee: Natera, Inc.
    Inventors: Aoy Tomita Mitchell, Michael Mitchell
  • Patent number: 12084722
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: September 10, 2024
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • Patent number: 12077820
    Abstract: The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TN-Falpha agents, for treatment with anti-?4?7 agents or with both anti-TNFalpha agent and anti-?4?7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-?4?7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: September 3, 2024
    Assignees: OSE IMMUNOTHERAPEUTICS, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Nicolas Poirier, Richard Danger